Evidence map›Paper›PMID 29323186›Full record

ArticleScientific reports2018

Combination of high-fat/high-fructose diet and low-dose streptozotocin to model long-term type-2 diabetes complications.

David André Barrière, Christophe Noll, Geneviève Roussy, Farah Lizotte, Anissa Kessai, Karyn Kirby, Karine Belleville, Nicolas Beaudet, Jean-Michel Longpré, André C Carpentier and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 162 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Experimental models in diabetes research.Laboratory animal research · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. The TRIM14-KIF1B Axis Drives Renal Injury in Diabetic Nephropathy Through TLR4/NF-κB Pathway Modulation.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

David André BarrièreDépartement de Pharmacologie et Physiologie/Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Québec, Canada. david.a.barriere@gmail.com.
Christophe NollDépartement de Médecine, Service d'Endocrinologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Québec, Canada.
Geneviève RoussyDépartement de Pharmacologie et Physiologie/Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Québec, Canada.
Farah LizotteDépartement de Médecine, Service d'Endocrinologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Québec, Canada.
Anissa KessaiDépartement de Pharmacologie et Physiologie/Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Québec, Canada.
Karyn KirbyDépartement de Pharmacologie et Physiologie/Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Québec, Canada.
Karine BellevilleDépartement de Pharmacologie et Physiologie/Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Québec, Canada.
Nicolas BeaudetDépartement de Pharmacologie et Physiologie/Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Québec, Canada.
Jean-Michel LongpréDépartement de Pharmacologie et Physiologie/Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Québec, Canada.
André C CarpentierDépartement de Médecine, Service d'Endocrinologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Québec, Canada.
Pedro GeraldesDépartement de Médecine, Service d'Endocrinologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Québec, Canada.ORCID http://orcid.org/0000-0002-2613-6710
Philippe SarretDépartement de Pharmacologie et Physiologie/Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Québec, Canada. philippe.sarret@usherbrooke.ca.
Université de Sherbrooke · CA

Funding

CIHR
6 · The paper itself

Abstract

The epidemic of type 2 diabetes mellitus (T2DM) is fueled by added fructose consumption. Here, we thus combined high-fat/high-fructose diet, with multiple low-dose injections of streptozotocin (HF/HF/Stz) to emulate the long-term complications of T2DM. HF/HF/Stz rats, monitored over 56 weeks, exhibited metabolic dysfunctions associated with the different stages of the T2DM disease progression in humans: an early prediabetic phase characterized by an hyperinsulinemic period with modest dysglycemia, followed by a late stage of T2DM with frank hyperglycemia, normalization of insulinemia, marked dyslipidemia, hepatic fibrosis and pancreatic β-cell failure. Histopathological analyses combined to [

Indexed as

AnimalsDiabetes ComplicationsDiabetes Mellitus, ExperimentalDiet, High-FatDisease ProgressionFluorodeoxyglucose F18FructoseHumansInsulin ResistanceMalePositron-Emission TomographyPrediabetic StateRatsStreptozocinFluorodeoxyglucose F18FructoseStreptozocin

Identifiers

PMID29323186
PMCPMC5765114
OpenAlexW2782132390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.